Latest news

• Roche buys gene therapy specialist Spark for $4.3bn

  Moreover, the deal also gives it multiple gene therapy candidates for haemophilia, a category the company broke into a couple of years ago with its fast-growing Hemlibra (emicizumab) antibody which

• Pfizer closes on EU approval of lung cancer drug Vizimpro

  Roche claimed a positive opinion for Hemlibra (emicizumab) for routine prophylaxis of bleeding episodes in adults and children with severe haemophilia A without factor VIII inhibitors, greatly extending the number if

• Ocrevus helps Roche shrug off biosimilars in 2018

  New haemophilia drug Hemlibra (emicizumab) added 224m francs, which Schwan said was ahead of expectations – and Esbriet (pirfenidone) for lung disease idiopathic pulmonary fibrosis (IPF) brought in just over 1bn francs,

• EMA sees approval numbers rise in 2018

  These were Roche’s Hemlibra, Shire’s Takhzyro, Alnylam’s Onpattro and Tegsedi. US shutdown and Brexit.

• Afinitor and Uptravi gain funding from NHS England

  The approvals capped a year of some notable market access deals struck between NHS England and the industry, including funding approval for Roche’s Hemlibra in July.